DUAL INCRETIN / AMYLIN RESEARCH COMBINATION
1 vial · lyophilized · ≥99% purity target
Research use only
This vial combines two research analogues: cagrilintide, a long-acting amylin-receptor agonist, and semaglutide, a GLP-1 receptor agonist. The pack states 5 mg + 5 mg. The vial mark “Cagrisema 10” is the house designation for that combined presentation. Both molecules belong to metabolic-hormone analogue classes used in laboratory study of appetite, energy balance and glycemic signaling. They are not presented here as licensed medicines.
Published work on this class examines dual amylin and GLP-1 receptor signaling in metabolic models: energy intake, body-weight biology and glycemic control in clinical and preclinical literature. Semaglutide is documented as a GLP-1 receptor agonist. Cagrilintide is documented as an amylin analogue. Combination studies treat the pair as a dual-agonist research approach. This page documents the material on file. It does not instruct use.
When a batch file is released, it will live here and on the compound dossier.